"Anti-Arrhythmia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
| Descriptor ID |
D000889
|
| MeSH Number(s) |
D27.505.954.411.097
|
| Concept/Terms |
Anti-Arrhythmia Agents- Anti-Arrhythmia Agents
- Agents, Anti-Arrhythmia
- Anti Arrhythmia Agents
- Antiarrhythmic Drugs
- Drugs, Antiarrhythmic
- Antiarrhythmia Agents
- Agents, Antiarrhythmia
- Antiarrhythmia Drugs
- Drugs, Antiarrhythmia
- Anti-Arrhythmia Drugs
- Anti Arrhythmia Drugs
- Drugs, Anti-Arrhythmia
- Anti-Arrhythmics
- Anti Arrhythmics
Cardiac Depressants- Cardiac Depressants
- Depressants, Cardiac
- Myocardial Depressants
- Depressants, Myocardial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Arrhythmia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Arrhythmia Agents".
This graph shows the total number of publications written about "Anti-Arrhythmia Agents" by people in this website by year, and whether "Anti-Arrhythmia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 2 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 4 | 1 | 5 |
| 2017 | 17 | 21 | 38 |
| 2018 | 17 | 21 | 38 |
| 2019 | 7 | 6 | 13 |
| 2020 | 5 | 3 | 8 |
| 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-Arrhythmia Agents" by people in Profiles.
-
Amiodarone as a possible therapy for coronavirus infection. Eur J Prev Cardiol. 2021 10 13; 28(12):e16-e18.
-
Covid-19 and development of heart failure: mystery and truth. Naunyn Schmiedebergs Arch Pharmacol. 2021 10; 394(10):2013-2021.
-
Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic. Rev Cardiovasc Med. 2021 03 30; 22(1):181-184.
-
COVID-19-related arrhythmias and the possible effects of ranolazine. Med Hypotheses. 2021 Apr; 149:110545.
-
Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study. Clin Transl Sci. 2021 05; 14(3):1092-1100.
-
Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown. J Interv Card Electrophysiol. 2022 Jan; 63(1):21-28.
-
Fulminant Bacillus cereus food poisoning with fatal multi-organ failure. BMJ Case Rep. 2021 Jan 18; 14(1).
-
COVID-19 FAQs in paediatric and congenital cardiology: AEPC position paper. Cardiol Young. 2021 Mar; 31(3):344-351.
-
A nontrivial differential diagnosis in COVID-19 pandemic: a case report and literary review of amiodarone-induced interstitial pneumonia. Future Cardiol. 2021 09; 17(6):991-997.
-
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. Eur J Clin Invest. 2021 Feb; 51(2):e13428.